Sherri Halloran

Virginia Bio
Vice President, Membership and Programs 

Robert Hamilton

Neural Analytics
VP of R&D 

Karl Handelsman

Life Science Angels Inc was founded in 2004 and is based in Sunnyvale CA. The group makes early-stage equity investments in a wide range of life science companies. Life Science Angels invests primarily in California but is open to investing out of state provided a round is being syndicated with a local angel group. Life Science Angels does not rule out investing outside the USA but has yet to do so. The group invests as individuals and allocation sizes are therefore highly varied but are usually of about $2-$6, Life Science Angels usually invests in rounds seeking $3 million or less. The group is interested in syndicating rounds with other angel groups.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Life Science Angels
Founder & Chairman 

Dr Carl Hansen Canada

AbCellera has developed a next generation technology for the analysis and screening of naturally derived immune repertoires. This platform uses high-throughput single cell analysis to enable the discovery of naturally derived monoclonal antibodies with unmatched speed, efficiency, and assay flexibility. By eliminating the need to culture cells this approach may be applied to antibody discovery from non-traditional host species, including rabbits and llamas, and achieves industry-leading capabilities in isolating antibodies from patient samples, with applications in infectious disease and autoimmunity.

AbCellera is engaged in antibody discovery projects with early partners, including biotech and pharma companies, and is also initiating internal programs aimed at using immune profiling for target identification and lead molecule discovery.

We are looking for Series A financing from strategic investors, as well as new partnerships with antibody drug development companies.

 

Dr Carl Hansen
AbCellera
CEO & President 

Glenn Harvin

TriNet
Regional Sales Consultant, Life Sciences and Biotech 

Masako Hashimoto

MBL Venture Capital founded in 2 is the investment arm of Medical & Biological Laboratories Co. a Japanese biotechnology company and is based in Nagoya Japan with an additional office in Tokyo. The firm primarily makes early stage investments solely in the Life Sciences. The firm recently raised a new fund in March 214 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally with particular interests in the USA and Europe. The firm is actively seeking new investment opportunities.
MBL Venture Capital
Senior Manager 

Yuri Haverman

BD Medical Surgical Systems
Strategic Innovation 

Mr Rob Hedequist United States

Kineta® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

Biotech Phase of Development
Technology Overview

Kineta® is developing a pipeline of next-generation medicines to respond to the needs of millions of people facing diseases around the world. Our scientific areas of expertise are immunology and neuropathic pain with research directed at curbing inflammation and returning the immune system to normal function. Kineta has five unique drug programs in development and each program represents a novel mechanism-of-action and has potential to result in a new class of drug. The innovative portfolio is derived from leading edge scientific research that taps into promising recently discovered cellular channels that control the body's defense mechanisms. Kineta’s drug programs are designed to enhance or modulate the natural human immune system and show great potential to be more effective, more tolerable and confer fewer side effects than existing drugs. We anticipate our products will be highly sought after by patients, healthcare providers and the pharmaceutical industry.

Alliance & Collaborations
27 Scientific and academic collaborations
Current Financing Needs

Series B round of $5M with follow on series C for an additional $20M.

Current Timeline

Autoimmune drug successfully completed phase I clinical trials and is currently in a phase 1B extension study to be completed 1st quarter.  In discussions with numerous large pharmaceutical and biotechnology companies around a licensing transaction.

Antiviral and pain programs are currently in pre-clinical development with high industry interest.  We are in significant partnering discussions around several of our anti-viral drug candidates.

Current Investors

We have raised $36M since 2008.  This has been augmented with an additional $52M in NIH funding.

Our current investors are accredited investors, high net worth individuals, Family Offices, a boutique PE group and the Iacocca Foundation.

IP Status
  Protected Pipeline Secured with a
Valuable IP Portfolio ØStrong IP across each development program ØProprietary expertise in innate immunity & autoimmunity Ø27 Patent Families (28 owned, 6 in-licensed) •45 Issued Patents •154 Pending country applications •7 Pre-nationalized PCT or provisional families
Management Team Highlights

Chuck Magness, PhD

CEO

Human Genome Project; Co-founded & Sold Illumigen Biosciences ($17M + 321M); Kineta Enterprise >$60M

Shawn Iadonato, PhD

CSO

Human Genome Project; Illumigen Biosciences; Grew 5 Kineta Programs; 1st Kv1.3 in Clinic; >$35M  R&D Funds

Craig Philips, MBA

Commercial Operations

 VP & GM, Schering Plough, VP & GM, Bayer, President & GM CTI

Blake Ilstrup, JD

General Counsel /

Corporate Dev.

Hundreds of transactions with Cooley and Venture Law Group, General Counsel of Qpass, 6 Kineta transactions

Rob Hedequist

Corporate Development

Major Accounts, Managed Care & Sales/ Marketing Pfizer and Amgen; National Director Schering–Plough

Dan Eramian

Corporate Communications

First VP of communications for Biotech Industry Organization; US DOJ Director of Public Affairs; SBA

Ken North

Corporate Development

Founding CEO Seattle Savings Bank; Past president Seattle Kiwanis, Chamber of Commerce; Seafair Commodores

Dan Burge, MD

Clinical

Trubion (CMO), VP Early Development Immunex, Amgen (early development on Enbrel)

Jeff Fellows

Regulatory

Global Regulatory Lead Amgen,  VP Regulatory Alder, VP Regulatory CTI,  First Kv1.3 in clinic, Sensipar Amgen

Kineta
Senior Vice President Corporate Development 

Martin Heidecker

Boehringer Ingelheim Venture Fund US Inc.
Managing Director 

Clay Heighten

Green Park & Golf Ventures (GPG) is a family office based in Dallas Texas. The firm was founded in 211 and is focused on healthcare companies. The firm makes seed venture and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $1K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.
Green Park & Golf Ventures
Founding Partner